Industry News

5 August 2025

LENZ Therapeutics announces USFDA approval of VIZZ for the Treatment of Presbyopia

LENZ Therapeutics, Inc announced the US Food and Drug Administration approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities to be initiated immediately.

5 August 2025

AbbVie's RINVOQ® Shows Promising Results in Phase 3 Trial for Severe Alopecia Areata

AbbVie announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 83.8 (approximately 16% scalp hair coverage).

1 August 2025

Trump Sends Ultimatum to Big Pharma : Slash Drug Prices or Face Action

US President Donald J. Trump has issued a sweeping ultimatum to 17 of the worlds largest pharmaceutical companies, demanding they drastically lower drug prices for Americans within 60 days or face aggressive regulatory and trade action.

24 July 2025

NATCO Pharma’s Mekaguda API unit receives EIR from U.S. FDA following June inspection

NATCO Pharmas Active Pharmaceutical Ingredient (API) facility located in Mekaguda, near Hyderabad, has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration

24 July 2025

Zydus receives tentative USFDA approval for Ibrutinib tablets in multiple strengths

Zydus Lifesciences Limited has received tentative approval from the U.S. Food and Drug Administration (USFDA) to market Ibrutinib tablets in three strengths — 140 mg, 280 mg, and 420 mg. The approved products are generic versions of Imbruvica®, a widely used cancer medication in the United States.

22 July 2025

Pharmaceutical Cold Chain Packaging market set to surpass USD 11.6 Billion by 2034 amid biologics boom

According to a recent industry report, the market is poised to reach USD 11.6 billion by 2034, nearly doubling its 2024–2025 valuation of around USD 6 billion, with a projected compound annual growth rate (CAGR) of approximately 6.8%.

22 July 2025

ADIA to Invest USD 200 Million in Meril

A wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) has entered into definitive agreements to invest USD 200 million for an approximately 3% stake in Micro Life Sciences Private Limited (Meril), one of India’s leading medical devices companies.

This investment values Meril at an enterprise value of USD 6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI).

19 July 2025

Johnson & Johnson receives USFDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

Johnson & Johnson that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200

18 July 2025

Knight Therapeutics announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Knight Therapeutics Inc. specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada.

17 July 2025

Corona Remedies acquires 7 Bayer brands, ahead of IPO

In a strategic move signaling its growing ambitions, Corona Remedies has acquired seven well-established pharmaceutical brands from Bayer’s Indian portfolio. The acquisition, effective July 16, 2025, includes one cardiology product and six widely used brands in the women’s health and fertility space.

Search

LENZ Therapeutics announces USFDA approval of VIZZ for the Treatment of Presbyopia

RECOMMENDED POSTS

Subscribe with us

Jobs by Category